Single Strain

BNR17

JUMP TO:
01
Summary

One study has examined Lactobacillus gasseri BNR17 in an IBS-D population. This study was excluded from our database due to several critical issues: lack of reported variability measures, apparent errors in the authors’ statistical calculations based on our independent review, and a significantly higher attrition rate in the probiotic group compared to the placebo group (20% vs. 10%, respectively). Given these evidence pitfalls, we cannot trust the findings of this study and have disqualified all results.

Key Takeaway:

Current available evidence is insufficient to recommend the use of Lactobacillus gasseri BNR17 in IBS at this time. 

Dosing Instructions: 

None, disqualified. 

 

 

References:

Shin SP, Choi YM, Kim WH, et al. A double blind, placebo-controlled, randomized clinical trial that breast milk derived-Lactobacillus gasseri BNR17 mitigated diarrhea-dominant irritable bowel syndrome. J Clin Biochem Nutr 2018;62(2):179-186. [doi: 10.3164/jcbn.17-73]

Read More…

One study has examined Lactobacillus gasseri BNR17 in an IBS-D population. This study was excluded from our database due to several critical issues: lack of reported variability measures, apparent errors in the authors’ statistical calculations based on our independent review, and a significantly higher attrition rate in the probiotic group compared to the placebo group (20% vs. 10%, respectively). Given these evidence pitfalls, we cannot trust the findings of this study and have disqualified all results.

Key Takeaway:

Current available evidence is insufficient to recommend the use of Lactobacillus gasseri BNR17 in IBS at this time. 

Dosing Instructions: 

None, disqualified. 

 

 

References:

Shin SP, Choi YM, Kim WH, et al. A double blind, placebo-controlled, randomized clinical trial that breast milk derived-Lactobacillus gasseri BNR17 mitigated diarrhea-dominant irritable bowel syndrome. J Clin Biochem Nutr 2018;62(2):179-186. [doi: 10.3164/jcbn.17-73]

Read More…
Find a probiotic with BNR17

There is insufficient evidence demonstrating benefits for IBS with this probiotic. Therefore, we do not provide guidance on finding a commercial product containing this strain/blend.

One study has examined Lactobacillus gasseri BNR17 in an IBS-D population. This study was excluded from our database due to several critical issues: lack of reported variability measures, apparent errors in the authors’ statistical calculations based on our independent review, and a significantly higher attrition rate in the probiotic group compared to the placebo group (20% vs. 10%, respectively). Given these evidence pitfalls, we cannot trust the findings of this study and have disqualified all results.

Key Takeaway:

Current available evidence is insufficient to recommend the use of Lactobacillus gasseri BNR17 in IBS at this time. 

Dosing Instructions: 

None, disqualified. 

 

 

References:

Shin SP, Choi YM, Kim WH, et al. A double blind, placebo-controlled, randomized clinical trial that breast milk derived-Lactobacillus gasseri BNR17 mitigated diarrhea-dominant irritable bowel syndrome. J Clin Biochem Nutr 2018;62(2):179-186. [doi: 10.3164/jcbn.17-73]

02
Results
Overall evidence quality grade
0%

This probiotic has low to moderate quality studies in IBS populations supporting it. View our evidence evaluation framework to learn how we assess the quality of studies.

Refine by Probiotic(s) In this view, show results

Close
  • Where trash
    trash

Add condition

03
Patient Handout
Share
04
Clinical Studies
  • #
  • Study
  • Year
  • Author(s)
  • Journal
  • Reference
  • Daily Dose
  • Duration of Intervention
  • Form
  • Study Design
  • Age
  • Participants
    • Study #1

    • A double blind, placebo-controlled, randomized clinical trial that breast milk derived-Lactobacillus gasseri BNR17 mitigated diarrhea-dominant irritable bowel syndrome

    • 2018
    • Shin SP, Choi YM, Kim WH, et al.

    • J Clin Biochem Nutr 2018;62(2):179-186

    • DOI:10.3164/jcbn.17-73
    • 10 billion CFU
    • 8 weeks
    • Capsule
      • RANDOMIZED
      • DOUBLE-BLIND
      • PLACEBO-CONTROLLED
      • PROSPECTIVE

    • ADULTS

    • ITT,PP (total) n=60,51
      ITT,PP (probiotic) n=30,24
      ITT,PP (placebo) n=30,27
05
Findings from studies

#

  • Diarrhea
  • Constipation
  • Bowel Habits
  • Global IBS Symptoms
  • Abdominal Pain / Discomfort
  • Bloating / Distention
  • Gas / Flatulence
  • Nausea / Vomiting
  • Mental Health
  • Quality of Life
  • Miscellaneous Symptoms
  • Notes

  • Study #1

    • Diarrhea

      • The probiotic led to a statistically significant improvement in colonic transit time (CTT), measured using a radiopaque capsule and abdominal x-ray. At baseline, the median interquartile range for transit time in the probiotic group was 5.4 hours, which increased to 19.2 hours by week 8.

      • This increase in CTT is considered a health improvement for IBS-D individuals with rapid transit times. The changes in CTT were statistically significant compared to the placebo group (p=0.0155).

      • We calculated an effect size of 0.84 for this parameter, which would have been classified within our moderate effect size range if the study had not been disqualified from consideration due to poor evidence quality.

    • Constipation

      • No data

    • Bowel Habits

      • There was no statistically significant improvement from baseline in mean defecation frequency within the probiotic group. However, there were statistically significant improvements from baseline for “days of troublesome IBS symptoms within 10 days” (p=0.0051), “disturbed daily life” (p=0.05), and “satisfied defecation” (p=0.0008).

      • No between-group statistical analysis was reported, and omitted data did not allow for our independent calculation of effect sizes.

    • Global IBS Symptoms

      • Comparisons between groups at week 4 and week 8 revealed no statistically significant differences in the subjective global assessment of IBS symptoms (p=0.4435 at week 4 and p=0.0879 at week 8).

    • Abdominal Pain / Discomfort

      • A statistically significant improvement from baseline for abdominal pain was observed in the probiotic group (p=0.0032). However, there was no statistical comparison between the probiotic and placebo groups, and the omitted data prevented us from independently calculating effect sizes.

    • Bloating / Distention

      • From baseline to week 8, there was a statistically significant improvement in distention within the probiotic group. However, no between-group statistical analysis was provided, and the omitted data prevented us from independently calculating effect sizes.

    • Gas / Flatulence

      • No data

    • Nausea / Vomiting

      • No data

    • Mental Health

      • No data

    • Quality of Life

      • Statistically significant improvements on the diarrhea-IBS QOL scale were observed at week 8 for several parameters: “Feels fatigue due to IBS symptoms” (p=0.0275), “Troublesome and not stable due to diarrhea symptoms” (p=0.0487), “Angry due to IBS symptoms” (p=0.0156), “Difficulty in social activities in the last four weeks” (p=0.028), “Exhausted due to IBS symptoms” (p=0.0159), and “Restricted and limited in familial activities” (p=0.0393).

      • However, there were no between-group comparisons for QOL measures, and omitted data prevented our independent calculation of effect sizes.

    • Miscellaneous Symptoms

      • There were no statistically significant differences between the groups for changes in glucose (mg/dL) and HbA1C (%).

    • Notes

      • This study was excluded due to several critical issues: lack of reported variability measures, apparent errors in the authors’ statistical calculations based on our independent review, and a significantly higher attrition rate in the probiotic group compared to the placebo group (20% vs. 10%, respectively).

      • Given these evidence pitfalls, we cannot trust the findings and have disqualified all results.